OBJECTIVES: Moderate or severe degree tricuspid valve regurgitation (TVR) is associated with high rates of morbidity and mortality. Surgical correction as the only therapeutic option offers unsatisfactory results. Recently, several interventional procedures have been introduced clinically in a limited cohort. We present our initial experiments with an innovative interventional valved stent graft for treatment of TVR.
INTRODUCTION
Tricuspid valve regurgitation (TVR) is a common finding during routine echocardiography in 80-90% of patients [1] . The most common pathomechanism causing TVR is dilatation of the annulus leading to functional regurgitation secondary to left-sided heart valve disease. Moderate or severe TVR is associated with high rates of morbidity and mortality and has been identified as an additional, independent risk factor for death [2] [3] [4] . Current therapy is limited either to medical treatment or to surgical correction by repair or replacement of the valve. However, surgical results are suboptimal. Despite good results reported by some groups, tricuspid valve surgery is associated with a high perioperative risk. Mortality rates of up to 10 .6% have been reported [5, 6] . Limited experience exists regarding long-term success, and high recurrence rates have been demonstrated [7, 8] . Also, reoperations of the tricuspid valve are associated with increased in-hospital and long-term deaths [9] .
The true incidence of moderate to severe TVR is difficult to determine, but some researchers have reported that at least moderate TVR is present in 24% of patients with symptomatic mitral valve disease [10] . Also, nearly 50% of patients present with increased severity of TVR of more than 2 grades after mitral valve surgery [11] . In addition, the incidence of TVR in patients with percutaneous mitral valve repair is high and has been confirmed to be an independent predictor of death and rehospitalization [12] .
Several strategies for interventional treatment of TVR have been described and applied to a small number of patients [13] . This limited experience has revealed the challenges of the interventional concept mostly because of various anatomical obstacles near the tricuspid annulus.
We have developed an innovative valved stent graft for a heterotopic implant into the right atrium. The aim of this study was to assess the feasibility of vascular access, delivery of the device and function of the valve in an ovine model as a proof of concept.
MATERIAL AND METHODS

Device specification
The prosthesis comprises a tubular stent graft with a laterally incorporated bicuspid valve. The stent frame is covered with porcine pericardium, as are the valve leaflets. The stabilizing structure is made of self-expandable Gianturco nitinol stents, and the axial nitinol stability bar valve is supported by 2 stent poles whose tips are bent outwards from the stent body. Radiopaque markers are incorporated into the cover material to allow for orientation of the valve during placement (Fig. 1) .
The device is loadable into a corresponding 22 Fr delivery system similar to conventional aortic stent delivery systems. A 'squeeze-torelease' mechanism for deployment allows for a controlled, stepwise implant. The device is fully retrievable until the valve component of the graft has been expanded. The delivery system is designed to be introduced into the femoral vein after surgical dissection. It is then advanced into the superior vena cava (SVC) under fluoroscopic guidance, where, after correct positioning, the prosthesis is released from the SVC to the inferior vena cava (IVC).
The cranial extension of the device is anchored in the distal SVC extending through the right atrium into the proximal segment of the IVC where the distal part of the device is anchored. The valve component is oriented towards the anterolateral aspect of the right atrium facing the orifice of the right atrial appendage, thus creating the physiological vortex [14, 15] (Fig. 2) .
For the animal trials, stent diameters of 22 mm and 30 mm were chosen for the SVC segment and the IVC segment, respectively.
In vitro setup
A model simulating the right heart was built using components of a ViVitro Pulse Duplicator (ViVitro Labs Inc., Victoria, Canada) and custom anatomical models to accommodate the valve (Fig. 3) . Flows and pressures were set to simulate the pathophysiological Figure 1 : Design of the bileaflet stent graft prosthesis. parameters of severe tricuspid regurgitation. After the device was connected to the simulator, the haemodynamic function of the valve was assessed by analysing the pressure and flow curves.
In a different setup, the devices were connected to an accelerated wear tester (HiCycle tester, ViVitro Labs Inc., Victoria, Canada) to assess long-term function and possible degeneration.
Human cadaver study
A human cadaver was prepared by thoracotomy and resection of the pericardium. The device was then implanted directly into the heart via the inferior vena cava. Device dimensions, anatomical fit and technical feasibility of the implant were assessed. After the device was put in position, silicone tubes were connected to the main pulmonary artery and the venae cavae. Tricuspid regurgitation was created by excising the septal leaflet of the tricuspid valve. A microcamera was implanted into the right atrial appendage. The heart was then connected to a perfusion system with a saline solution to simulate blood flow across the prosthesis. During manual compression of the heart, movement of the stent valve was assessed.
Animal model and implanted device
Seven domestic adult female sheep (64-93 kg, median 75 kg) were included in the study. All sheep were housed and fed according to European Union and German laws. All procedures were approved by the responsible authority under the supervision of the local animal welfare officer. One week after arrival in the facility, food was withheld from the animals for 24 h before the procedure. They were premedicated with atropine (0.05 mg/kg body weight) and azaperone (4 mg/kg body weight), both administered intramuscularly. The sheep were anaesthetized with ketamine (8-14 mg/kg body weight) and midazolam (0.2-1 mg/kg body weight) administered intravenously through a peripheral catheter placed in an ear vein on each side. Anaesthesia was maintained with continuous intravenous infusion of propofol (2-5 mg/kg body weight) and inhalation of isoflurane (0.8-1.6 vol%). In addition, analgesia was induced by continuous intravenous infusion of fentanyl (30-100 mg/kg body weight/h). All animals were intubated endotracheally, and a rumen tube was put in place. Mechanical volumecontrolled ventilation was initiated with an FiO 2 of 0.5 (Draeger Zeus, Luebeck, Germany). This protocol represents the standard protocol; individual adjustments were made according to the judgment of the responsible veterinarian.
Monitoring of the animals included continuous documentation of body temperature, electrocardiographic results, pulse oximetry and arterial and central venous pressures (IntelliVue MP5, Philips Medical Systems, Hamburg, Germany).
Both the carotid artery and jugular vein were dissected through an incision in the skin on the left side of the neck. An arterial pressure line and central venous line were then introduced directly. The animal was placed in a right decubitus position. The left hip was rotated externally to expose the left groin. The femoral vein was dissected through a small skin incision and mobilized at the level of the inguinal ligament. The vessel was prepared with a purse-sting suture (Prolene 5/0, Ethicon, Hamburg, Germany). Heparin was administered intravenously at a dose to reach a targeted activated clotting time of 250 s. After puncture under visual control, the implanted sheath (Easy Plus 22 Fr, Jotec, Hechingen, Germany) was advanced using an Amplatz super stiff guidewire (Boston Scientific, Marlborough, MA, USA) using Seldinger's technique under fluoroscopic control (BV Pulsera, Philips Medical Systems, Hamburg, Germany).
Under fluoroscopic control, a standard 5 Fr pigtail catheter was positioned in the SVC using a flexible guidewire (Radiofocus, Terumo, Leuven, Belgium). Using the catheter, an Amplatz super stiff guidewire (Boston Scientific) was placed into the SVC. After removal of the pigtail catheter, the delivery catheter was introduced over the guidewire and the device was positioned under fluoroscopic guidance. The valve was then implanted in the above-mentioned stepwise fashion. The delivery system was removed via the implant sheath.
Sealing of the stent in both caval veins and valve function were documented by angiograms. In addition, transthoracic echocardiography was performed in the last 4 animals to determine device position and visualize inflow via the new valve (Vivid e, General Electric Healthcare, Little Chalfont, UK).
After the device was implanted, the sheath was removed, and vascular integrity was restored by the previously placed pursestring suture.
After a postimplant observational period of 30 min, the animals were sacrificed by the veterinarian according to the approved institutional protocol.
In all instances, necropsy was performed with removal of the heart and adjacent vessels for controlled ex situ dissection. Device positioning was assessed in relation to the specific anatomy of each animal and compared to the angiograms and transthoracic echocardiograms obtained during the procedure.
RESULTS
Human cadaver study
The cadaver study showed a good anatomical fit of the specific device used (22-mm SVC, 38-mm IVC segments) with correct sealing and safe anchoring inside both caval veins as well as an unobstructed position of the valve element inside the right atrium. Different infusions heights were used to alter inflow pressures. The created flow showed that minimal pressure differences (<5 mmHg) were sufficient for the valve element to operate, showing good opening and closing behaviour.
In vitro tests
The right heart simulator was set up with an insufficient biological valve in the tricuspid position, and the flow conditions were set up to create a cardiac output of 5 l/min at a ventricular pressure of 60 mmHg over 15 mmHg. The incompetent tricuspid valve caused a significant v-wave with an amplitude of 40 mmHg traced in the right atrium. The device (22-mm SVC, 28-mm IVC segments) was then implanted into the system resulting in complete elimination of backflow and in pulsatility in the caval veins. At 5 l/min of cardiac output, no gradient was measured across the valve.
Animal model
The devices were custom made, and the dimensions such as length and diameter were estimated according to the individual sizes and weights of the animals. Based on the experience of each experiment, the dimensions of the device dimensions were adjusted after the completion of each experiment (Table 1) .
Vascular access could be established successfully without the need for laparotomy via the femoral veins in all animals (n = 7). After removal of the sheath and the implant system, permanent haemostasis could be achieved without stenosis of the femoral vein.
The device was implanted successfully in all animals. There were no technical complications related to mechanics of the device or the implant system. Device orientation was correct in all instances. There were no vascular or cardiac complications such as perforation, bleeding, pericardial haemorrhage or significant arrhythmia. Implant time, defined as the time between insertion of the delivery system and deployment of the valve, was between 3 and 15 min with an average of 8 ± 4.48 min (Table 1) .
In all animals, the device showed a correct function with traceable opening and closing of the valve component under fluoroscopy. In all but one instance, proper sealing of the device could be demonstrated by angiography. The animal (#3) was of unusual dimensions (93 kg body weight). Due to a considerable dilatation, especially of the SVC, anchoring of the device was not ideal with subsequent device migration. Valve function was still correct, but necropsy revealed the position of the device to be too cranial. In all other animals, valve position and function was demonstrated to be correct as judged by angiography (Fig. 4) . In the last 4 animals, echocardiography was performed before and after the implant. The preimplant study was used to confirm SVC diameters and to document right atrial and ventricular dimensions as well as to rule out preoperative tricuspid regurgitation. Postimplant studies were performed to assess device position and to confirm unimpaired flow across the new valve (Fig. 5) . TVR was created using a dedicated catheter only in the last 3 animals in this series. Success of this model was confirmed by echocardiography.
Pressure traces obtained by 'pull-back' pressure measurements in the native right ventricle, native right atrium and inside the graft demonstrated correct sealing of the neoatrium from the native ventricle and atrium by the new valve (Fig. 6) .
All animals survived the implant procedure and remained in a stable cardiopulmonary condition during the postimplant observation period. They could then be sacrificed according to protocol. Necropsy showed acceptable positioning of the device in all animals and a correct position in 6 animals. Correct orientation of the valve segment facing towards the right atrial appendage was confirmed in all animals (Fig. 7) .
DISCUSSION
Although the long-term prognosis of moderate to severe TVR has repeatedly been demonstrated to be poor, only a few patients are considered for surgical therapy [6, 13] , most likely due to suboptimal results reported by several groups [7, 9, 16, 17] . The true incidence of significant TVR remains unknown, but the increasing population of high-risk patients with symptomatic left heart valve disease makes it reasonable to assume a rising incidence of moderate or severe degree TVR. Because this highrisk patient cohort is obviously not suitable for operative therapy, a less invasive, preferably catheter-based treatment option is needed.
The pathophysiologic characteristics of TVR are complex and develop over time in a stepwise fashion. As symptoms such as peripheral oedema, ascites, pleural effusion and hepatic dysfunction appear, quality of life is impaired due to frequent hospitalizations. In a later phase, right ventricular failure develops and has a poor prognosis.
In the recent past, several devices have been developed for interventional treatment of TVR. So far, only a few patients have been treated [13, [18] [19] [20] , revealing several difficulties and obstacles. These devices can be divided into 2 groups: those that are designed to correct the problem at the level of the annulus, the goal being to restore normal physiological cardiac function, and those designed to eliminate or decrease venous backflow to increase quality of life.
In the first group of devices, several anatomical obstacles have been encountered. Large, complex annuli, fragile valve tissue, the highly anatomically variable subvalvular apparatus, anatomically close coronary sinus and AV-node and the absent calcifications impede implants of currently available interventional valve prostheses. Also, the unfavourable angle between the caval veins and the tricuspid annulus and the thin-walled, intensely trabeculated right ventricle impede transvascular or transapical access. The design of delivery systems with large-diameter valves and the presence of a pacemaker or defibrillator leads could further limit their suitability. To avoid these obstacles, some devices like spacers or those for tricuspid annuloplasty have been developed to augment coaptation. In a highly selected, limited patient cohort, these devices have been applied clinically. The initial results have been promising; however, follow-up is currently limited to only a few months. Some groups have achieved favourable results with transapical implants of a valved stent graft in a porcine model [19] [20] [21] [22] [23] .
Alternatively, valve implants at the level of the caval veins have been introduced with interventional balloon-expandable or selfexpanding devices [24, 25] . The large, variable diameter of the caval veins in the presence of severe regurgitation and the proximity of the right atrium, the coronary sinus, and hepatic veins to the stent graft represent the challenges of implanting valves at the level of the caval veins.
The results of the initial experience in this limited patient cohort (cumulative 33 patients), as judged by the success of the implants and the reduction in tricuspid regurgitation, are promising; however, peri-interventional deaths are reported to be as high as 20% [13] .
Blood flow in the right atrium is complex due to cardiac looping during embryonic development and to 3 different inflow sources (superior and inferior vena cava and coronary sinus). A vortex-like, forward rotation of blood has repeatedly been demonstrated in healthy subjects [14, 15] . The investigated device was designed to combine the facility of implanting a caval valve with the conservation or restoration of this physiological blood flow due to the position of the valve. Possible further advantages of the device might be the reduction of right atrial volume and wall stress. The custom-made, self-expandable, pericardium-covered stent design might facilitate the implant and reduce injury to the fragile wall tissue of the dilated and thinned caval wall.
According to the results achieved in this study, the concept of this innovative device could be confirmed both in the laboratory and in in vivo settings. Simulating the pathophysiology of severe tricuspid regurgitation in our in vitro model, the connection of the valved stent with the circulation completely restored normal physiology without the presence of a significant gradient across the new valve. Our in vivo results clearly demonstrate the feasibility of vascular access and the reliable, and safe deployment of the device with 100% functionality of the implanted bicuspid valve. No complications during stent graft implant occurred, nor did we encounter any obstruction from adjacent anatomical structures, i.e. the coronary sinus. In this setting, the heterotopic concept proved to be valid with a simple 1-step implant technique, which can be performed by a single surgeon. Unlike other approaches, no preparation such as prestenting of the caval veins or of the annulus was necessary due to the innovative design of the device. The device exhibited correct haemodynamic function for the experimental period until each experiment was terminated as judged by haemodynamic monitoring and echocardiography. No animal was sacrificed due to haemodynamic instability. Treatment of the animals other than by fluid substitution was not necessary. Even in the absence of tricuspid regurgitation, blood flow across the stent valve could be visualized by both echocardiography and angiography. We were able to establish a reproducible tricuspid regurgitation model only in the last 3 animals. Those animals tolerated the induction of TVR well during the short experimental period under general anaesthesia. Due to the obvious limitations of this initial experimental investigation, haemodynamic performance and the benefit of the device in the presence of tricuspid regurgitation remain to be proven in a larger series with chronic regurgitation. We hope to reproduce the increase of cardiac output after valve implant observed ex vivo in the long-term in vivo model.
To date, no information is available regarding the functional and anatomical changes of the right heart and caval veins in a long-term model. Dilatation of the caval veins is likely to occur. Because determination of correct stent dimensions has proved difficult in our preliminary model, correct sizing of the device remains a challenge. Also, the success of the direct transfer of this procedure to humans remains unclear. Tricuspid regurgitation in sheep might not cause haemodynamic changes similar to those in humans and might not necessarily lead to heart failure in the quadruped [26] . However, because clinical findings similar to those observed in humans, such as congestion, are observed in the sheep, it seems reasonable to assume that implanting the device should result in improvement of haemodynamics even in the absence of heart failure.
We obtained the correct dimensions of the device for the experimental setup from the cadaver trial. However, the quality of the tissue of the anatomical specimens was not comparable to that in vivo. We expect high inter-and intraindividual variability of the vascular dimensions in vivo. Therefore, visualization and measurement of the caval vein diameters and of the distance between the SVC and IVC before the implant procedure are essential. The devices will have to be manufactured individually to guarantee correct fitting, which includes achieving an oversizing of 10-15%.
In general, the consequences of the competence of the previously chronically regurgitant tricuspid valve have to be considered. Especially in the presence of an elevated right ventricular afterload due to pulmonary hypertension, the risk for acute or subacute right heart failure may be increased. The fate and the physiological consequences of the ventricularisation of the right atrium are unknown. The subsequent dynamically reduced right ventricular compliance could result in a reduction of right ventricular stroke volume. In the long-term, these changes might favour the development or exacerbation of right ventricular failure. In addition, the unchanged volume load of the right atrium could cause further, progressive dilatation of the caval veins, thereby increasing the risk of an endoleak of the stent.
The frequent presence of pacemaker or defibrillator leads in this patient population might limit the feasibility of an interventional therapeutic approach and is even considered a contraindication for transcatheter tricuspid valve repair techniques. The innovative, unique design of our device utilizes a self-expandable stent with a porcine pericardium cover. Because both materials are known to have good sealing qualities, the device is likely to be beneficial when implanted in the presence of pacemaker or defibrillator leads.
The device is designed primarily to relieve the symptoms of venous backflow. Most likely, right ventricular failure and dilatation cannot be treated with this approach because the native valve remains regurgitant. A positive effect of decreased regurgitant volume and a possible increase in cardiac output cannot be excluded at this point. Further studies in a long-term tricuspid regurgitation animal model are necessary to better understand the haemodynamic effects.
Device-related complications such as fatigue or degeneration of the device are also an important issue in the evaluation of the devicé s safety. The data generated ex vivo in an accelerated wear tester indicate correct device function for more than 12 months. The low-flow area of the right atrium in the presence of initial impairment of the right ventricle and atrial fibrillation might increase the risk of device thrombosis. We believe this risk to be of minimal relevance because most patients are taking anticoagulant medications to treat chronic atrial fibrillation. The results of the long-term animal trial have to be reviewed to answer the question of device-induced thrombosis.
This initial, limited experience provides the proof of concept for this innovative device. The facilitated 1-step deployment and the independence of valvular anatomy should result in a fast, easy, highly reproducible implant procedure for this high-risk patient cohort. So far, questions of haemodynamic performance in the presence of severe tricuspid regurgitation, haemocompatibility, possible complications and side effects and long-term function have not been addressed and need to be investigated in a long-term experimental model.
